Across TCGA pan-cancer cohorts, GALM Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GALM data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GALM Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GALM expression acts as an unfavorable survival marker.
HNSC and SKCM are the cancer types where GALM Mutation most reproducibly stratifies survival.